Neuropsychiatric aspects of Huntington’s disease

J S Paulsen, R E Ready, J M Hamilton, M S Mega, J L Cummings

Abstract

Objective—Neuropsychiatric symptoms are common in Huntington’s disease and have been considered its presenting manifestation. Research characterising these symptoms in Huntington’s disease is variable, however, encumbered by limitations within and across studies. Gaining a better understanding of neuropsychiatric symptoms is essential, as these symptoms have implications for disease management, prognosis, and quality of life for patients and caregivers.

Method—Fifty two patients with Huntington’s disease were administered standardised measures of cognition, psychiatric symptoms, and motor abnormalities. Patient caregivers were administered the neuropsychiatric inventory.

Results—Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety. Symptoms ranged from mild to severe and were unrelated to dementia and chorea.

Conclusions—Neuropsychiatric symptoms are prevalent in Huntington’s disease and are relatively independent of cognitive and motor aspects of the disease. Hypothesised links between neuropsychiatric symptoms of Huntington’s disease and frontal-striatal circuitry were explored. Findings indicate that dimensional measures of neuropsychiatric symptoms are essential to capture the full range of pathology in Huntington’s disease and are vital to include in a comprehensive assessment of the disease.

Keywords: Huntington’s disease; neuropsychiatry; dementia

Neurologists should be aware that Huntington’s disease is characterised by a triad of symptoms including motor disturbance, cognitive impairment, and psychiatric features. Although it is well established that psychiatric symptoms are common in Huntington’s disease, research and clinical emphases have been on motor and cognitive aspects of the disorder. Reconsideration of the psychiatric manifestations of the disease is warranted. Firstly, psychiatric disturbances are most strongly associated with stress, disability, and placement decisions. Secondly, there is evidence that brain changes precede the traditional clinical diagnosis and psychiatric manifestations may predate motor signs by a decade. Finally, clinical trials are underway to slow Huntington’s disease progression in clinically affected patients with plans to treat “preclinical” patients imminent. Careful study of neuropsychiatric symptoms associated with Huntington’s disease is essential to help distinguish features that are pathognomonic from behaviours that are sensitive but not specific of the disease. Models emphasising the role of the basal ganglia in neuropsychiatric disorders have been described over the past several decades. One recent overview suggests that because the earliest pathological changes in Huntington’s disease are in the associative portions of the striatum, the behaviours first affected by disease may be cognitive and psychiatric, rather than motor.

Indeed, reviews of psychiatric symptoms in Huntington’s disease have suggested that depression, apathy, aggression, and disinhibition are common and suicide rates are over three times those of the general population. Previous studies have used an array of data collection methods, however, and standardised uniform assessment of psychiatric features in Huntington’s disease is lacking. The purpose of the current study is to use the well established neuropsychiatric inventory (NPI) to better characterise psychiatric symptoms in the disease.

Methods

SAMPLE

Participants were 52 consecutive patients with Huntington’s disease recruited from the Huntington’s Disease Clinical Research Program at the University of California at San Diego (n=29) and from the University of Iowa Huntington’s Disease Society of America Center of Excellence (n=23). The diagnosis was made by a senior staff neurologist based on the presence of an unequivocal movement disorder in a person with a family history of Huntington’s disease. All diagnoses were confirmed by DNA analysis for CAG expansion in the IT15 region of chromosome 4. All consecutive persons with an unequivocal diagnosis attending the UCSD Huntington’s disease clinic between 1994 and 1997 or attending the University of Iowa Huntington’s disease clinic between 1997 and 1999 were approached for inclusion in the study. No patient refused participation in the study. Four patients were excluded from the study for the following reasons: (a) having a medical illness other than Huntington’s disease (n=1); (b) having a history of head trauma with loss of consciousness (n=1); and (c) having an age of onset younger than 18 (n=2). Patients were 52% women with a mean age of 45.5 (SD 11.7) years (range 26–78) and a mean of 13.3 (SD 2.3) (range 6–17) years of education.

Duration of disease (number of years since diagnosis) ranged from 0 to 20 years (mean 4.7 (SD 4.4)). Age of onset of illness ranged from
Neuropsychiatric aspects of Huntington's disease

25 to 57 with a mean of 43.1 (SD 9.6). There were no juvenile onset cases included in this study. Mini mental state examination\(^1\) (MMSE) scores ranged from 7 to 30 (mean 24.34 (SD 4.38), and Mattis dementia rating scale\(^18\) (DRS) scores ranged from 63 to 142 (mean 122 (SD 15.6)). Total chorea scores (assessed with the unified Huntington's disease rating scale\(^19\) (UHDRS) ranged from 0 to 26 (assessed with the unified Huntington's disease rating scale\(^18\) (UHDRS) ranged from 0 to 26 (mean 12.4 (SD 7.4)). Over 79% of patients were taking no medication (n=41). Four patients were taking a selective serotonin reuptake inhibitor (SSRI) and a typical neuroleptic drug, although dosages of the neuroleptic drug were very low in every case (<5 mg). One patient was taking an atypical neuroleptic drug. Four patients were taking SSRIs only and one patient was taking trazodone at bedtime for sleep. No patients were taking tetrabenazine. Analyses conducted with and without the subsample of patients taking psychotropic medications did not differ.

**PROCEDURE**

Huntington’s disease caregivers (n=52) were interviewed with the neuropsychiatric inventory\(^\dagger\) (NPI) by JSP or a trained research assistant. The NPI assesses the frequency (four point rating scale) and severity (three point scale) of 10 neuropsychiatric disturbances (delusions, hallucinations, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour), and a score from 0 to 12 was obtained for each scale by multiplying frequency by severity. An NPI total score was calculated by summing ratings for all symptoms. The NPI offers advantages over previous psychiatric research in Huntington’s disease; it is standardised, is not influenced by normal aging, it is used to characterise various neurological disorders,\(^20-22\) and it is used as a measure of treatment response\(^20\) and in investigations of the biological correlates of neuropsychiatric symptoms. Informant reports of psychiatric symptoms in patients with neurodegenerative disease are commonly used and have been found to agree significantly with self reports.\(^21\)

Patients were administered the DRS and MMSE cognitive screening tests and the UHDRS as a measure of chorea severity. Scores on the MMSE were unavailable for two patients. After complete description of the study to the patients and caregivers as approved by the institutional review boards of both universities, informed consent was obtained.

Neuropsychiatric symptoms were not normally distributed. Therefore, all analyses used non-parametric tests. Specifically, Spearman correlation coefficients were used to examine associations between factors, and Mann Whitney \(U\) tests were used for all comparisons of means. Due to the many analyses, a significance level of 0.01 was selected to control for multiple comparisons and to guard against type I errors.

<table>
<thead>
<tr>
<th>NPI Scale</th>
<th>Frequency*</th>
<th>Mean†</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysphoria</td>
<td>69.2</td>
<td>3.12</td>
<td>3.46</td>
</tr>
<tr>
<td>Agitation</td>
<td>67.3</td>
<td>2.88</td>
<td>3.32</td>
</tr>
<tr>
<td>Irritability</td>
<td>65.4</td>
<td>2.63</td>
<td>3.11</td>
</tr>
<tr>
<td>Apathy</td>
<td>55.8</td>
<td>2.79</td>
<td>4.02</td>
</tr>
<tr>
<td>Anxiety</td>
<td>51.9</td>
<td>1.96</td>
<td>3.14</td>
</tr>
<tr>
<td>Disinhibition</td>
<td>34.6</td>
<td>1.29</td>
<td>2.77</td>
</tr>
<tr>
<td>Euphoria</td>
<td>30.8</td>
<td>1.04</td>
<td>2.27</td>
</tr>
<tr>
<td>Delusions</td>
<td>11.5</td>
<td>0.75</td>
<td>2.63</td>
</tr>
<tr>
<td>Aberrant motor</td>
<td>9.6</td>
<td>0.60</td>
<td>2.18</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>1.9</td>
<td>0.23</td>
<td>1.66</td>
</tr>
</tbody>
</table>

\(n=52\).

NPI=Neuropsychiatric inventory.

*Per cent of patients with HD with an NPI scale score \(\geq 1\).

†Mean scores are averages of frequency/ severity ratings.

**Results**

**NEUROPSYCHIATRIC SYMPTOM PREVALENCE**

Only one patient did not exhibit any neuropsychiatric symptoms. The most often endorsed symptoms were dysphoria (69.2%), agitation (67.3%), irritability (65.4%), apathy (55.8%), and anxiety (51.9%). These symptoms also had the highest mean scale scores, which reflect frequency and severity ratings. Delusions (11.5%), aberrant motor behaviour (9.6%), and hallucinations (1.9%) were the least prevalent and had the lowest frequency by severity mean ratings (table 1).

**ASSOCIATIONS OF NPI WITH DEMOGRAPHIC AND DISEASE MEASURES**

The total NPI score was negatively correlated with years of education (\(r=-0.37\)). Mann Whitney \(U\) tests comparing symptom means in male and female patients showed no significant differences. Age was negatively correlated with disinhibition (\(r=-0.41\)) and delusions (\(r=-0.36\)). Illness duration and chorea severity were not significantly associated with any NPI scores (table 2).

Neither measure of dementia severity (MMSE, DRS) was significantly correlated with neuropsychiatric symptoms (table 2). The DRS initiation and perseveration subscale showed a significant positive correlation with delusions (\(r=0.36\)). DRS attention was positively correlated with NPI aberrant motor behaviour (\(r=0.37\)) and dysphoria (\(r=0.41\)). DRS conceptualisation was positively correlated with aberrant motor behaviour (\(r=0.37\)). DRS supermarket verbal fluency was positively correlated with delusions (\(r=0.38\)).

**NEUROPSYCHIATRIC SYMPTOM INTERCORRELATIONS**

Intercorrelations with the NPI scale were investigated to assess associations among symptoms and to determine if symptom associations found in other neuropsychiatric populations were replicated. Nine significant symptom associations were found (table 3). The high correlation (\(r=0.81\)) between irritability and agitation suggests that these two scales are essentially measuring the same construct in this sample of patients with Huntington’s disease.

Three of the significant NPI symptom associations (agitation and irritability, anxiety and dysphoria, disinhibition, and irritability) were
Table 2 Correlations between NPI neuropsychiatric symptoms and motor and cognitive measures for patients with HD

<table>
<thead>
<tr>
<th>NPI Scale</th>
<th>Chorea</th>
<th>MMSE†</th>
<th>DRS‡</th>
<th>Attention</th>
<th>Conceptualisation</th>
<th>Construction</th>
<th>Initiation and perseveration</th>
<th>Memory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agitation</td>
<td>−0.02</td>
<td>−0.09</td>
<td>−0.11</td>
<td>−0.15</td>
<td>−0.13</td>
<td>0.02</td>
<td>−0.10</td>
<td>−0.01</td>
</tr>
<tr>
<td>Dysphoria</td>
<td>−0.18</td>
<td>0.11</td>
<td>0.30</td>
<td>0.41**</td>
<td>0.25</td>
<td>−0.21</td>
<td>0.29</td>
<td>−0.05</td>
</tr>
<tr>
<td>Irritability</td>
<td>−0.14</td>
<td>−0.09</td>
<td>−0.08</td>
<td>−0.23</td>
<td>−0.18</td>
<td>−0.08</td>
<td>0.01</td>
<td>−0.00</td>
</tr>
<tr>
<td>Anxiety</td>
<td>0.11</td>
<td>0.06</td>
<td>0.09</td>
<td>0.13</td>
<td>0.11</td>
<td>−0.01</td>
<td>0.06</td>
<td>−0.03</td>
</tr>
<tr>
<td>Apathy</td>
<td>−0.12</td>
<td>−0.15</td>
<td>−0.07</td>
<td>−0.12</td>
<td>−0.16</td>
<td>0.04</td>
<td>−0.17</td>
<td>−0.17</td>
</tr>
<tr>
<td>Euphoria</td>
<td>0.17</td>
<td>−0.08</td>
<td>0.06</td>
<td>−0.07</td>
<td>0.09</td>
<td>0.09</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Delusions</td>
<td>−0.05</td>
<td>−0.10</td>
<td>−0.24</td>
<td>−0.23</td>
<td>−0.09</td>
<td>0.04</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>Apathy</td>
<td>−0.23</td>
<td>0.22</td>
<td>0.06</td>
<td>0.07</td>
<td>−0.09</td>
<td>0.36**</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>Hallucinations</td>
<td>−0.12</td>
<td>0.21</td>
<td>0.15</td>
<td>0.09</td>
<td>0.11</td>
<td>0.20</td>
<td>−0.12</td>
<td></td>
</tr>
<tr>
<td>NPITotal</td>
<td>−0.03</td>
<td>0.01</td>
<td>0.04</td>
<td>−0.03</td>
<td>−0.12</td>
<td>−0.11</td>
<td>−0.02</td>
<td></td>
</tr>
</tbody>
</table>

NPI=Neuropsychiatric inventory; DRS=Mattis dementia rating scale; MMSE=mini mental state examination; HD=Huntington’s disease.†n=50; ‡n=52.

Table 3 NPI neuropsychiatric symptom correlations in Huntington’s disease

<table>
<thead>
<tr>
<th>NPI Scale</th>
<th>Agitation</th>
<th>Dysphoria</th>
<th>Irritability</th>
<th>Anxiety</th>
<th>Apathy</th>
<th>Euphoria</th>
<th>Delusions</th>
<th>Apathy</th>
<th>Irritability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysphoria</td>
<td>0.26</td>
<td>0.81*</td>
<td>0.41*</td>
<td>0.40*</td>
<td>0.43*</td>
<td></td>
<td>0.38*</td>
<td>0.34</td>
<td>0.22</td>
</tr>
<tr>
<td>Irritability</td>
<td>0.14</td>
<td>0.14</td>
<td>0.25</td>
<td>0.35</td>
<td>0.37*</td>
<td>0.37**</td>
<td>0.08</td>
<td>0.30</td>
<td>0.09</td>
</tr>
<tr>
<td>Anxiety</td>
<td>0.30</td>
<td>0.10</td>
<td>0.34</td>
<td>0.37*</td>
<td>0.21</td>
<td>0.27</td>
<td>0.30</td>
<td>0.27</td>
<td>0.09*</td>
</tr>
<tr>
<td>Apathy</td>
<td>0.09</td>
<td>0.09</td>
<td>0.02</td>
<td>0.08</td>
<td>0.09</td>
<td>0.09</td>
<td>0.02</td>
<td>0.02</td>
<td>0.40*</td>
</tr>
<tr>
<td>Euphoria</td>
<td>0.38*</td>
<td>0.34</td>
<td>0.30</td>
<td>0.37*</td>
<td>0.27</td>
<td>0.27</td>
<td>0.30</td>
<td>0.27</td>
<td>0.27</td>
</tr>
<tr>
<td>Delusions</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.28</td>
</tr>
<tr>
<td>Apathy</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−0.01</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>−0.17</td>
<td>0.23</td>
<td>0.13</td>
<td>0.24</td>
<td>0.23</td>
<td>0.23</td>
<td>0.09</td>
<td>0.24</td>
<td>0.24</td>
</tr>
</tbody>
</table>

n=52.

NPI=Neuropsychiatric inventory. *p <0.01.

also significant (p<0.01) in an Alzheimer’s disease (n=50) sample.22 Two significant associations from this sample (apathy and aberrant motor behaviour, dysphoria, and irritability) were not replicated. A significant association between anxiety and agitation found in a sample (n=22) of patients with progressive supranuclear palsy was replicated in the Huntington’s disease sample.

Discussion

Neuropsychiatric symptoms were common in this Huntington’s disease sample, with 98% of patients exhibiting at least one symptom during the previous month. This total incidence is higher than that found in other dementias2 and greater than previously reported in patients with other basal ganglia disorders2 also using the NPI. Findings are consistent, however, with other estimates of psychiatric symptoms in Huntington’s disease.1–4

The NPI scale includes anxiety, irritability, apathy, and dysphoria as symptoms. Anxiety was present in over 50% of the sample, whereas psychotic symptoms (delusions and hallucinations) and aberrant motor behaviour were rare. Findings from this investigation are consistent with and enlarge past research on neuropsychiatric aspects of Huntington’s disease. Specifically, previous findings indicating that affective disorders’ and symptoms’ are common in Huntington’s disease were replicated. Apathy and irritability have similarly been found to be evident in about half of patients with Huntington’s disease.25

Given the input and output nuclei of the basal ganglia, it is not surprising that rates of neuropsychiatric symptoms are consistently high in Huntington’s disease. The dorsolateral subcortical circuit projects from dorsal, anterior, and lateral regions of the prefrontal cortex via the dorsolateral head of the caudate, to the ventral anterior and medial dorsal nuclei of the thalamus, and plays a part in complex cognitive processes including working memory, generative behaviours, and the ability to establish and shift from one topic to another. Impairments in these so called “executive functions” also affect various aspects of emotional and behavioural control. For instance, regulatory functions of the circuit (generating and shifting) may alter the appropriate expression of frustration, resulting in apparent irritability and agitation.

The orbitofrontal circuit projects from the anterior and lateral orbitofrontal cortex via the ventromedial caudate nucleus to the ventral anterior and medial dorsal nuclei of the thalamus, and has been associated with disorders including depression and obsessive-compulsive disorder. Most clinical and research reports have found that in virtually all cases, the manifestation of depression was either simultaneous with or after the motor onset of Huntington’s disease, suggesting that depression in Huntington’s disease is likely due to the disease process. Given that most patients in the current study were prescribed antidepressant medications, it is likely that rates of depression in Huntington’s disease are much higher than that reported in the literature.

The medial prefrontal circuit projects from the paralimbic cortical territories (postero medial orbitofrontal cortex and anterior cingulate) via the nucleus accumbens to the medial dorsal nucleus within the thalamus, and plays a
Neuropsychiatric aspects of Huntington's disease

part in response inhibition. Dysfunction of the
cortical circuit produces apathy, which has been
shown to increase with illness duration in
Huntington's disease. These findings are
consistent with the known degeneration in the
disease, progressing from mediofrontal and
dorsal to ventral caudate, possibly impact-
ing on the orbital and dorsolateral circuits
before the cingulate circuit. Although apathy
was noted in over 50% of patients with Hunt-
ington's disease, Litvan et al28 showed that
patients with hypokinetic movement disorders
were more likely to demonstrate hypoactive
behaviours, such as apathy, whereas patients
with hyperkinetic movement disorders (for
example, Huntington's disease) demonstrated
relatively more hyperactive behaviours (agita-
tion, irritability, and anxiety). This behavioural
dissociation is consistent with circuitry involve-
ment, suggesting hypoactive behaviours in per-
sons with cingulate disruption and hyperactive
behaviours in people with orbito/dorsal dys-
function.

Associations found between neuropsychiatric
symptoms and demographic factors sug-
gested that younger patients were more likely
to experience psychotic symptoms and to be dis-
inhibited. Although this finding is consistent
with anecdotal reports, the pathophysiology of
this association (age and psychosis) is un-
known. It is possible that onset of Huntington's
disease at an earlier age disrupts frontostriatal
circuitry that is not fully developed, resulting in
variations in phenotype. Alternatively, other
mediating factors likely exist to account for the
variability in age of Huntington's disease onset.
It is possible that genetic factors influencing
age at onset also impact on behavioural pheno-
type so that mechanisms influencing earlier
onset also increase the probability of psychosis.
Given that CAG repeat length accounts for
only half of the variance in age of onset,29 addi-
tional research is needed to better understand
Huntington's disease phenotype and onset
heterogeneity.

The increased breadth and dimensional
assessment of neuropsychiatric symptoms
provided by this study showed that patients
with Huntington's disease exhibited the full
range of symptomatology, from mild to severe,
as indicated by NPI frequency and severity
ratings. Thus, assessment tools that rely on
categorical diagnostic criteria to assess psychi-
atric aspects of Huntington's disease would
likely fail to detect the significant proportion
of patients with subthreshold symptoms.
Dimensional assessment tools, such as the
NPI, may aid in the detection of mild or atypical
cases of neuropsychiatric disorders and
allow the capture of a full range of symptoma-
tology. Neuropsychiatric assessment at varying
degrees of severity also is important because
these symptoms can be targeted for interven-
tion and assessment can be used to track
change over time during the natural course of
the disease, or used to measure response to
treatment.

Consistent with previous reports,25 few asso-
ciations were found between neuropsychiatric
symptoms and measures of cognitive or motor
signs. Specifically, the MMSE, total DRS, cho-
rea severity, and disease duration were not sig-
ificantly correlated with any neuropsychiatric
symptom. These findings are consistent with
other research31 and indicate that behavioural
aspects of basal ganglia diseases are often inde-
pendent of cognitive and motor symptoms, at
least early in the disease.

Findings from this study have important
implications for clinical neuropsychiatry. The
current study suggests that nearly all patients
with Huntington's disease experience psy-
chiatric symptoms. In addition, recent research
as well as anecdotal evidence implies that psychi-
atric symptoms may be the first manifestation
of disease in up to 79% of patients.3 It is likely,
then, that clinical neuropsychiatrists may be
among the professionals first and most often
seen by persons with Huntington's disease.
Unfortunately, specific training for behavioural
management of patients with Huntington's
disease is not typically available in general psy-
chiatry and neurology programmes. Results of
this study suggest that the infrequent patient
with Huntington's disease should be consid-
ered an opportunity for training and that
psychiatric assessment should be a standard
component of the Huntington's disease evalu-
ation. Excellent references for treatment can
be found in Rosenblatt et al30 and Leroi and
Michalon.31

This study was supported by National Institutes of Mental
Health (NIMH) grants (R03MH5331–05 and
K02MH01579–01), a National Institutes of Neurological
Disorders and Stroke grant (PO410951–G), a Howard Hughes
Medical Institute Pilot Grant, and a Carver Medical Research
Initiative Grant Award to JSH, a National Institute on Aging
(NIA) Alzheimer's Disease Research Center grant, an
Alzheimer's Disease Research Center of California grant, and
the Siddell-Kagan Foundation to JLC; a NIA grant to MSM
(K08 AG100784); a NIMH grant (RO3MH59430–01) to JMH;
and a NIH/NIA (T32AG006214) fellowship to RER.

1 Caine ED, Shoulson I. Psychiatric syndromes in Hunting-
2 Cummings JL. Behavioral and psychiatric syndromes associ-
Behavioral neuroscience of movement disorders. New York;
3 Folsom SE, Foltz SE. Psychiatric features of Hunting-
ton's disease: recent approaches and findings [review]. Psy-
4 Shiwhach R. Psychopathology in Huntington's disease's patients.
5 Morris M. Psychiatric aspects of Huntington's disease. In:
Harper PS, ed. Huntington's disease. London: WB Saun-
6 Dewhurst K, Oliver JI, McKnight AL. Socio-psychiatric
consequences of Huntington's disease. Br J Psychiatry
7 Gutknecht C, S YI, B et al. Nuclear and neuropil aggre-
gates in Huntington's disease: relationship to neuropathology.
8 Cina JH, Kosinski CM, Kerner JA, et al. Altered brain neu-
rotransmitter receptors in transgenic mice expressing a
portion of an abnormal human Huntington disease gene.
9 Nauta WJ, Mehlner WR. Projections of the lentiform nucleus
10 Swerdlow NR, Koob GF. Lesions of the dorsomedial
nucleus of the thalamus, medial prefrontal cortex and
caudate-putamen: the effects on locomotor activity
mediated by nucleus accumbens-ventral pallidal circuitry.
Brain Res 1987;212:23–43.
11 Cummings JL. Frontal-subcortical circuits and human
12 Vonsattel JP, Delong M. Huntington's disease [review]. J
13 Middleton FA, Strick PL. Basal ganglia and cerebellar
loops: motor and cognitive circuits. Brain Res 2000;80;
236–50.
14 Di Maio L, Suenitri F, Napolitano G, et al. Suicide risk in


